This trial will study a type of breast cancer defined by the expression of hormone receptor in the cancer cells (HR+). Patients will be treated with ribociclib, a cyclin-dependent kinase inhibitor, and camizestrant, a selective estrogen receptor degrader (SERD) and complete ER antagonist. The main purpose of the Study is to analyze the efficacy (to find out how effective a treatment is) of ribociclib in combination with camizestrant in patients with advanced HR+ breast cancer who have received endocrine therapy (ET) in early breast cancer setting for at least 5 years, of which at least 2 years with aromatase inhibitor (AI). Ribociclib plus camizestrant efficacy will be determined by assessing the period from treatment initiation until disease progression, defined as progression free survival (PFS).
The anticipated favorable clinical benefits of the combination of ribociclib and camizestrant therapy are projected to outweigh the risks of this treatment. This Study will be performed in full compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and all applicable local Good Clinical Practice (GCP) and regulations.

Start Date01 Dec 2025

Sponsor / Collaborator

Medica Scientia Innovation Research SL

ChiCTR2500111780

/ Not yet recruitingPhase 4IIT

A Multicenter Randomized Controlled Clinical Trial of Neoadjuvant Endocrine Therapy versus Chemotherapy in Patients with HR+/HER2- Early-Stage Breast Cancer

Start Date15 Nov 2025

Sponsor / Collaborator

Sun Yat-Sen Memorial Hospital

[+2]

NCT07085767

/ Not yet recruitingPhase 3

A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Start Date31 Oct 2025

Sponsor / Collaborator

Olema Pharmaceuticals, Inc.

[+1]

100 Clinical Results associated with Ribociclib Succinate

100 Translational Medicine associated with Ribociclib Succinate

100 Patents (Medical) associated with Ribociclib Succinate

1,298

Literatures (Medical) associated with Ribociclib Succinate

01 Jan 2026·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Multi-omics integrative analysis elucidates the molecular characteristics of SMARCA4-deficient lung adenocarcinoma and the derived therapeutic options

Article

Author: Dong, Wei ; Chi, Yuxiang ; Wang, Kai ; Du, Jiajun ; Guo, Deyu ; Sun, Shijie

SMARCA4-deficient lung adenocarcinoma (LUAD) is highly aggressive with multiple oncogene mutations, and has low sensitivity to chemotherapy, targeted therapy and immunotherapy. By integrating multi-omics analysis and machine learning analysis on 20 lung adenocarcinoma datasets, we characterized SMARCA4 mutation in clinical prognosis, metabolic level, immune infiltration and pathway enrichment. The key role of SMARCA4 in LUAD development was confirmed by several in vitro and in vivo experiments. SMARCA4 is highly expressed in LUAD tissues compared with adjacent tissues, and SMARCA4 mutation is a poor prognostic factor. Although SMARCA4-deficient LUAD patients are not sensitive to common chemotherapeutic drugs, immunotherapy is an alternative treatment for lung adenocarcinoma. SMARCA4 deletion is associated with a high rate of oncogene co-mutation. Co-mutation of KRAS was found to have a significant impact on the response to multiple types of chemotherapy. Unique metabolic profiles, abnormal cell cycle and hyperactivation of oxidative phosphorylation were hallmarks of SMARCA4 mutant LUAD. We screened four chemotherapeutic agents targeting MTOR pathway, oxidative stress, DNA replication or cell cycle, including rapamycin and ribociclib, as potential chemotherapeutic agents for SMARCA4-deficient lung adenocarcinoma. In vitro assays showed that SMARCA4 knockdown significantly inhibited DNA replication, cell cycle and cell proliferation in lung adenocarcinoma cells, and significantly promoted oxidative stress and apoptosis in lung adenocarcinoma cells. Our comprehensive findings advance our understanding of SMARCA4 mutant LUAD gene mutation and immune microenvironment, providing insights into potential therapeutic approaches and research directions for SMARCA4-deficient LUAD.

01 Jan 2026·Radiology case reports

Symptomatic bone marrow involvement by metastatic occult HR+/HER2- breast cancer treated with ribociclib and letrozole: A case report

Article

Author: Golemba, Alfredo S ; Tolosa, Raúl E García ; Aguirre Santamaría, Astor A ; Jimenez Bolaño, Adriana L

Visceral crisis (VC) occurs in less than about 15% of patients with de novo metastatic breast cancer (BC). We present a case of a 59-years-old woman who presented with history of bone pain, fatigue, dyspnea on exertion, and weight loss; on physical examination was found no breast nodules, enlarged lymph nodes, or enlarged viscera were palpable. Laboratory tests revealed hemoglobin 5.8 g/dl. PET CT scan showed multiple osteolytic lesions. A bone marrow biopsy was performed, which identified infiltration by an epithelial tumor lesion. Immunohistochemistry showed positivity for CK1/3, CK7, Gata-3, and estrogen and progesterone receptors. HER2 negative (0+). The diagnosis of de novo occult HR+/HER2- metastatic BC was made. Systemic treatment with ribociclib and letrozole was started; the patient experienced clinical improvement of the symptoms, weight gain and improvement in hemoglobin levels. VC in HR+/HER2- metastatic BC is a challenging situation from its definition to its management. In case of availability and quick access, a free CT regimen with CDK4/6i + endocrine therapy could be a option to consider in this patients. This also represents a challenge in terms of cost-effectiveness in the health systems of low-income countries.

01 Dec 2025·Eating Behaviors

Medications as precipitating factors for potential eating disorders: A disproportionality analysis using FDA adverse event reports

Article

Author: Zhang, Shuang ; Zheng, Liyun

OBJECTIVE:

Compared to psychosocial factors, medications remain less well recognized as precipitating factors for eating disorders. This study aims to identify medications potentially associated with eating disorders using the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) database.

METHODS:

FAERS reports related to potential eating disorders from January 2004 to December 2024 were retrieved. Reporting odds ratios (RORs) were calculated to detect disproportionate signals, with Fisher's exact test and Bonferroni correction applied for adjustments in multiple comparisons. Drugs exhibiting significant positive signals (ROR 95 % confidence interval lower bound >1, adjusted p-value < 0.01) with over 100 reports were selected for LASSO regression analysis. Logistic regression, adjusted for age, sex, and reporter type, was employed to identify precipitating drugs.

RESULTS:

Among 20,145 reports, 62.7 % involved females, with a median age of 59 years (interquartile range: 42-71). Thirty drugs showed significant positive signals. Nine potential precipitating medications were identified through LASSO and logistic regression, including octreotide, ribociclib, sunitinib, rivastigmine, everolimus, quetiapine, palbociclib, esomeprazole, and pregabalin.

CONCLUSION:

This study identifies certain medications that may act as precipitating factors for potential eating disorders, particularly in middle-aged and older populations. Clinicians should monitor these medications that affect appetite, weight, or carry abuse potential to prevent harm, especially in patients with eating disorders or at-risk populations.

392

News (Medical) associated with Ribociclib Succinate

28 Oct 2025

·www.fiercepharma.com

Newer drugs came to Novartis’ aid as 2 top-selling blockbusters stalled in Q3

Novartis CEO Vas Narasimhan suggested that investors focus more on the growths of the Swiss pharma's newer drugs such as Kisqali, Pluvicto, Scemblix and Kesimpta. Novartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto.The erosion was obvious. After MSN Pharmaceuticals opened the floodgates to Entresto generics in the U.S. late July, sales of Entresto went from a 22% year-on-year increase at constant currencies in the second quarter to a 1% decline in the third quarter.The drug’s third-quarter sales were $1.88 billion, down from $2.36 billion during the three months that ended in June. In the U.S., specifically, Entresto brought in 13% fewer sales than a year ago, dropping below $800 million in the third quarter.After years of lawsuits and petitions with the FDA, Novartis failed to secure an injunction against generics of the heart failure and hypertension therapy before the key patent exclusivity expired. The Swiss pharma is still in litigation with a generic manufacturer and the FDA, according to the company’s third-quarter financial report.While Wall Street had expected Entresto’s decline, the slowdown of Novartis’ second-top-selling product, inflammatory and autoimmune disease treatment Cosentyx, came as a bit of a surprise. Compared to a 6% sales growth at constant currencies in the second quarter, the drug saw sales dip 1% in the third quarter to slightly below $1.7 billion.Cosentyx sales were affected by a one-time $74 million rebate adjustment in the U.S., as well as pricing discounts outside the U.S., according to Novartis. But these one-time effects were only part of Cosentyx’s problem. Novartis has been playing defense in the relatively new market of hidradenitis suppurativa (HS) after UCB’s rival biologic Bimzelx entered the chronic skin condition field in November 2024.After an initial dip, Cosentyx has reached a “stabilization of the performance” in HS, Novartis CEO Vas Narasimhan said on the company’s third-quarter earnings call Tuesday. The drug now holds 52% of the new-to-brand share in treatment-naïve patients and 50% overall in the disease setting.The company has become better at convincing doctors to step up Cosentyx dosing rather than switching patients off the drug if they don’t respond well, Narasimhan said, explaining that now Novartis is turning its focus to overall HS market expansion.However, Narasimhan acknowledged that the market growth has been slower than what Novartis had originally expected.“We continue to see this as a $3 billion to $5 billion-plus market, but it’s clearly going to take longer for that market to develop,” Narasimhan said. Despite those two brands underperforming, Novartis still delivered 7% groupwide sales growth at constant currencies, reaching $13.9 billion in the third quarter, thanks to a group of newer medicines. And Narasimhan suggests investors move on from the aging blockbusters, too.“I would focus much more on the dynamic growth you saw in the quarter on Kisqali, Pluvicto, Scemblix, Kesimpta, all of which, to my eyes, were ahead of consensus,” Narasimhan said on the call. “That’s where I think the focus should be now looking ahead for the company.”Leading the charge was Kisqali, whose $1.33 billion haul marked a 68% increase year over year at constant currencies. The drug is benefiting from an early breast cancer indication, where it’s leading the CDK4/6 competition with 63% new-to-brand share in the U.S.Kisqali is only in the middle of its growth story, according to Narasimhan. In early breast cancer, the drug boasts an advantage over Eli Lilly’s Verzenio thanks to a broader label that also includes patients without nodal involvement. In that exclusive population, more than 60% of eligible patients are still not on a CDK4/6 inhibitor, he said.Meanwhile, the Kisqali launch in the early breast cancer indication is only just beginning outside the U.S., where the drug registered 37% sales growth at constant currencies during the third quarter. The first launch markets are trailing on a similar trajectory as in the U.S., Narasimhan said. In Germany, Kisqali’s monthly new-to-brand share in the early cancer setting was at 77% as of July, according to Novartis.The biggest beat of the quarter for Novartis came from Kesimpta, which brought in $1.22 billion sales on the strength of a 44% year-over-year increase at constant exchange rates, or 9% ahead of analysts’ expectations.The growth was impressive considering increased competition in multiple sclerosis, including the September 2024 entry of a subcutaneous version of Roche’s popular biologic Ocrevus. Asked by one analyst on Tuesday’s call whether any unusual factors contributed to the drug’s performance, Novartis CFO Harry Kirsch confirmed it was “mainly underlying operation growth—a little bit of inventory, but not much.”Elsewhere, radioligand therapy Pluvicto racked up $564 million sales, good for 45% growth year over year at constant currencies. Novartis is preparing an FDA filing for Pluvicto in metastatic hormone-sensitive prostate cancer by the end of the year, hoping to double the size of the drug’s target patient population.Moreover, the PCSK9 cholesterol drug Leqvio is on track for blockbuster status with $894 million sales in the first nine months of 2025, including $308 million during the third quarter.While Leqvio marked one of Novartis’ early investments in RNA therapies, the Swiss pharma has just agreed to pay $12 billion to acquire Avidity Biosciences, which is developing a new class of RNA therapeutics called antibody-oligonucleotide conjugates. The entire pharmaceutical industry is currently navigating policy changes in the U.S. Three companies—Pfizer, AstraZeneca and Merck KGaA’s EMD Serono—have signed “most favored nation” drug pricing deals with the Trump administration. Novartis is “meeting with the administration weekly to look at what are the best solutions we can come up with,” Narasimhan said on the investor call.Facing looming threats of U.S. tariffs on pharmaceuticals, Novartis in April unveiled a $23 billion U.S. investment plan. The majority of the investment will be related to R&D and reflected in Novartis’ financial statements as operating expenses, Kirsch explained on Tuesday’s call. Some of it will be capital expenditures, such as manufacturing expansions, but Kirsch said this part is more about reallocating resources from other parts of the world to the U.S., rather than increasing overall company spending.

AcquisitionDrug Approval

28 Oct 2025

·pharma.economictimes.indiatimes.com

Novartis hits profit target as new drugs offset drag from generics

Frankfurt: Swiss drugmaker Novartis met third-quarter profit forecasts on Tuesday, as fast growth of newer drugs offset a sharp slowdown in blockbuster heart drug Entresto as it comes under pressure from generics in the U.S. market. The results underscore why Novartis is on an aggressive deal-making spree this year, with a push for acquisitions and licensing deals worth up to $30 billion so far to bolster its drug pipeline as established treatments lose patent protection. The company, which has raised its outlook twice this year, confirmed its 2025 forecasts and said it expected net sales to grow by a "high single-digit" percentage and adjusted operating income to grow by a "low-teens" percentage. Operating income, adjusted for special items, rose 6% to $5.46 billion in the quarter, just slightly above consensus numbers cited by analysts of $5.4 billion. CEO SEES NO IMPACT FROM US TRADE TARIFFS CEO Vas Narasimhan said on an earnings call that the company did not expect a hit from U.S. trade tariffs, despite President Donald Trump threatening levies on drugmakers and pushing for lower drug prices for Americans and more local investment. "We expect five different groundbreakings before the end of the year at manufacturing sites in the U.S. So no impact from tariffs on our guidance for the remainder of this year and next year," said Narasimhan. He said talks over drug pricing with the U.S. administration were progressing well. Peers including Pfizer and AstraZeneca have already struck drug-pricing deals. In late September, Trump said he would impose a 100% tariff on imports of branded or patented pharmaceuticals, starting October 1, unless a drugmaker is building manufacturing facilities in the United States. NEW DRUGS VS GENERICS Novartis has been on a buying spree as it looks to firm-up its drug pipeline in the face of "increasing generic erosion" in the United States. This week it unveiled a $12 billion deal for U.S. biotech firm Avidity. Quarterly sales of its established heart drug Entresto, which lost patent protection this year, reached $1.88 billion in the third quarter, compared to $1.77 billion expected by analysts, according to LSEG data. That was largely flat versus a year ago, well down from its 20%-plus growth earlier in the year. REVENUE FROM TOP SELLER SEEN DECLINING Launched a decade ago, Entresto was Novartis' top-selling medicine in 2024 with sales of $7.82 billion worldwide. In July, a U.S. federal judge rejected Novartis' request to stop MSN Pharmaceuticals from selling a generic version. Analysts project revenue from the drug will surpass $8 billion this year, but will drop to about $6 billion in 2026, according to LSEG data. Sales of the firm's psoriasis drug Cosentyx, which faces competition in the treatment of certain types of psoriasis and arthritis from UCB's Bimzelx, were mostly flat year-on-year at about $1.7 billion. Sales of breast cancer drug Kisqali, launched last year, came in at $1.33 billion. (Reporting by Ludwig Burger in Frankfurt and Bhanvi Satija in London; Editing by Janane Venkatraman and David Holmes)>

BiosimilarFinancial StatementDrug Approval

28 Oct 2025

·www.globenewswire.com

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +7% (cc1, +8% USD) and core operating income1 grew +7% (cc, +6% USD) Sales growth was driven by continued strong execution on priority brands including Kisqali (+68% cc), Kesimpta (+44% cc), Pluvicto (+45% cc) and Scemblix (+95% cc)Core operating income margin1 was stable (cc) at 39.3% despite increasing generic impact Q3 operating income grew +27% (cc, +24% USD); net income rose +25% (cc, +23% USD)Q3 core EPS1 grew +10% (cc, +9% USD) to USD 2.25Q3 free cash flow1 was USD 6.2 billion (+4% USD) driven by higher net cash flows from operating activitiesStrong nine months performance with net sales up +11% (cc, +11% USD) and core operating income up +18% (cc, +16% USD)Q3 selected innovation milestones: Rhapsido FDA approval as the only oral, targeted BTK inhibitor for CSU Ianalumab positive replicate Phase III readouts in Sjogren’s diseasePluvicto positive Phase III PSMAddition data at ESMOScemblix positive CHMP opinion for all lines of CML treatmentCosentyx positive Phase III readout in PMRFabhalta positive Phase III eGFR readout in IgA nephropathy Full-year 2025 guidance2 reaffirmed Sales expected to grow high single-digitCore operating income expected to grow low-teens 1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 42 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance assumptions on page 7. Basel, October 28, 2025 – Commenting on Q3 2025 results, Vas Narasimhan, CEO of Novartis, said:“Novartis delivered solid financial performance in Q3, more than offsetting the impact of increasing generic erosion in the US. Our key growth drivers performed well, including Kisqali, Kesimpta, Pluvicto and Scemblix. Importantly, we achieved FDA approval for Rhapsido in CSU and positive Phase III readouts for ianalumab in Sjogren’s disease – two assets with pipeline-in-a-pill potential that could underpin our growth through 2030 and beyond. In addition, we completed several deals in the quarter to further strengthen our pipeline in core therapeutic areas. We remain well on track to achieve our guidance for 2025 and over the mid-term." Key figures Q3 2025Q3 2024% change9M 20259M 2024% change USD mUSD mUSDcc USD mUSD mUSDccNet sales13 90912 82387 41 19637 1641111Operating income4 5013 6272427 14 02811 0142731Net income3 9303 1852325 11 5639 1192729EPS (USD)2.041.582931 5.944.503235Free cash flow6 2175 9654 15 94112 61826 Core operating income5 4605 14567 16 96014 6351618Core net income4 3304 13356 13 52211 8221417Core EPS (USD)2.252.06910 6.945.831921 Strategy Our focus Novartis is a “pure-play” innovative medicines company. We have a clear focus on four core therapeutic areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple significant in-market and pipeline assets in each of these areas, that address high disease burden and have substantial growth potential. In addition to two established technology platforms (chemistry and biotherapeutics), three emerging platforms (gene & cell therapy, radioligand therapy and xRNA) are being prioritized for continued investment into new R&D capabilities and manufacturing scale. Geographically, we are focused on growing in our priority geographies – the US, China, Germany and Japan. Our priorities Accelerate growth: Renewed attention to deliver high-value medicines (NMEs) and focus on launch excellence, with a rich pipeline across our core therapeutic areas.Deliver returns: Continuing to embed operational excellence and deliver improved financials. Novartis remains disciplined and shareholder-focused in our approach to capital allocation, with substantial cash generation and a strong capital structure supporting continued flexibility. Strengthen foundations: Unleashing the power of our people, scaling data science and technology and continuing to build trust with society. Financials Third quarter Net sales were USD 13.9 billion (+8%, +7% cc), with volume contributing 16 percentage points to growth. Generic competition had a negative impact of 7 percentage points, driven by Promacta, Tasigna and Entresto generics in the US. Pricing had a negative impact of 2 percentage points, driven by revenue deduction adjustments mainly in the US. Currency had a positive impact of 1 percentage point. Operating income was USD 4.5 billion (+24%, +27% cc), mainly driven by higher net sales and lower impairments, partly offset by higher R&D investments. Net income was USD 3.9 billion (+23%, +25% cc), mainly driven by higher operating income. EPS was USD 2.04 (+29%, +31% cc), benefiting from the lower weighted average number of shares outstanding. Core operating income was USD 5.5 billion (+6%, +7% cc), mainly driven by higher net sales, partly offset by higher R&D investments. Core operating income margin was 39.3% of net sales (-0.8 percentage points, stable in cc). Core net income was USD 4.3 billion (+5%, +6% cc), mainly due to higher core operating income, partly offset by other core financial income and expense. Core EPS was USD 2.25 (+9%, +10% cc), benefiting from the lower weighted average number of shares outstanding. Free cash flow amounted to USD 6.2 billion (+4% USD), compared with USD 6.0 billion in the prior-year quarter, driven by higher net cash flows from operating activities. Nine months Net sales were USD 41.2 billion (+11%, +11% cc), with volume contributing 14 percentage points to growth. Generic competition had a negative impact of 3 percentage points, while pricing and currency had no impact. Operating income was USD 14.0 billion (+27%, +31% cc), mainly driven by higher net sales and lower impairments, partly offset by higher investments behind priority brands and launches. Net income was USD 11.6 billion (+27%, +29% cc), mainly driven by higher operating income. EPS was USD 5.94 (+32%, +35% cc), benefiting from the lower weighted average number of shares outstanding. Core operating income was USD 17.0 billion (+16%, +18% cc), mainly driven by higher net sales, partly offset by higher investments behind priority brands and launches. Core operating income margin was 41.2% of net sales, increasing 1.8 percentage points (2.5 percentage points cc). Core net income was USD 13.5 billion (+14%, +17% cc), mainly due to higher core operating income. Core EPS was USD 6.94 (+19%, +21% cc), benefiting from the lower weighted average number of shares outstanding. Free cash flow amounted to USD 15.9 billion (+26% USD), compared with USD 12.6 billion in the prior-year period, driven by higher net cash flows from operating activities. Q3 priority brands Underpinning our financial results in the quarter is a continued focus on key growth drivers (ranked in order of contribution to Q3 growth) including: Kisqali(USD 1 329 million, +68% cc) sales grew strongly across all regions, including +91% growth in the US with strong momentum from the recently launched early breast cancer indication as well as continued share gains in metastatic breast cancer.Kesimpta(USD 1 222 million, +44% cc) sales grew across all regions driven by increased demand and strong access.Pluvicto(USD 564 million, +45% cc) showed sustained demand growth in the US following the pre-taxane metastatic castration-resistant prostate cancer (mCRPC) approval, as well as continued access expansion ex-US in the post-taxane mCRPC setting, with 25 countries now approved including Japan.Scemblix(USD 358 million, +95% cc) sales grew across all regions, demonstrating the continued high unmet need in CML, with strong momentum from the early-line indication in the US and Japan.Leqvio(USD 308 million, +54% cc) continued steady growth across all regions, with a focus on increasing account and patient adoption, and continuing medical education.Fabhalta(USD 149 million, +236% cc) sales grew, reflecting market share gains in PNH globally and continued launch progress in IgAN and C3G in the US.Lutathera(USD 213 million, +11% cc) sales grew mainly in the US, Japan and Europe due to increased demand and earlier-line adoption.Cosentyx(USD 1 698 million, -1% cc) sales were broadly stable, as strong volume growth in the US was partially offset by higher revenue deductions, and ex-US declined due to a one-time price effect in the prior year. Novartis remains confident in Cosentyx USD 8 billion+ peak sales guidance.Zolgensma(USD 301 million, -5% cc) sales declined reflecting a lower incidence of SMA compared to prior year. Net sales of the top 20 brands in the third quarter and nine months Q3 2025% change9M 2025% change USD mUSDccUSD mUSDccEntresto1 8771-16 4951515Cosentyx- excl. revenue deduction adjust.*1 69805-144 8617979Kisqali1 32969683 4626263Kesimpta1 22246443 1984140Tafinlar + Mekinist550311 67599Jakavi539841 55576Promacta/Revolade362-36-381 410-14-14Pluvicto56446451 3893333Ilaris47327261 3692524Xolair440531 33988Tasigna221-47-48925-27-26Zolgensma301-2-5925-3-4SandostatinGroup302-1-1922-5-5Scemblix35897958948584Leqvio30856548636361Lutathera21312116131514ExforgeGroup1761054602Lucentis148-40-42510-39-39DiovanGroup143-5-5447-10GalvusGroup126-21-20373-19-16Top 20 brands total11 35010933 7711414 *Sales growth impacted by a one-time revenue deduction adjustment in the US R&D update - key developments from the third quarter New approvals Rhapsido(remibrutinib)Rhapsido was approved by the FDA as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. It is the first FDA-approved Bruton’s tyrosine kinase inhibitor (BTKi) for CSU. Remibrutinib is also in Phase III development for chronic inducible urticaria, hidradenitis suppurativa and food allergy, as well as multiple sclerosis and myasthenia gravis. Regulatory updates Scemblix (asciminib)The CHMP of the EMA adopted a positive opinion and recommended granting marketing authorization for Scemblix for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) in all lines of treatment. Results from ongoing trials and other highlights Ianalumab(VAY736)The Phase III NEPTUNUS-1 and -2 trials evaluating ianalumab in adults with active Sjögren’s disease met their primary endpoint, showing statistically significant improvements in disease activity as measured by a reduction in ESSDAI compared to placebo. Ianalumab was well tolerated and demonstrated a favorable safety profile, supporting its potential to become the first targeted treatment for this chronic autoimmune disease. Novartis plans to submit ianalumab to health authorities globally and was granted Fast Track Designation by the FDA. In the Phase III VAYHIT2 trial, ianalumab plus eltrombopag significantly extended the time to treatment failure compared to placebo plus eltrombopag in adult patients with primary immune thrombocytopenia (ITP), previously treated with corticosteroids. The safety profile was consistent with previous studies. Data will be presented at an upcoming medical meeting and included in regulatory submissions in 2027.Ianalumab is also in Phase III development for systemic lupus erythematosus, lupus nephritis and warm autoimmune hemolytic anemia.Pluvicto(lutetium Lu177 vipivotide tetraxetan)In the Phase III PSMAddition trial, Pluvicto plus standard-of-care (SoC) reduced risk of progression or death by 28% versus SoC alone, with a positive trend in overall survival in patients with PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC). Safety remained consistent with PSMAfore and VISION trials. Data presented at ESMO.Kisqali(ribociclib)The five-year analysis of the pivotal Phase III NATALEE trial in the broadest population of high-risk stage II and III HR+/HER2- early breast cancer (eBC) showed the addition of Kisqali to endocrine therapy (ET) reduced the risk of recurrence by 28.4% compared to ET alone. Data also showed a 29.1% risk reduction in distant disease-free survival, a positive trend in overall survival, and no new safety signals. Data presented at ESMO.Cosentyx(secukinumab)The Phase III REPLENISH study met its primary endpoint, with Cosentyx demonstrating statistically significant and clinically meaningful sustained remission compared to placebo at week 52 in adults with relapsing polymyalgia rheumatica (PMR). Full data will be presented at an upcoming medical congress and submitted to health authorities in 2026.Fabhalta(iptacopan)In the Phase III APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful superiority compared to placebo in slowing IgAN progression measured by annualized total slope of estimated glomerular filtration rate (eGFR) decline over two years. Full data will be presented at future medical meetings and included in regulatory submissions in 2026.Leqvio(Inclisiran)In the Phase IV V-DIFFERENCE study, 85% of patients with hypercholesterolemia who had not reached guideline-recommended LDL-C targets despite optimized lipid-lowering therapy (LLT) achieved their goals with Leqvio plus LLT, versus 31% with placebo plus LLT, with benefits evident in as early as 30 days. Leqvio also reduced LDL-C by 59% over 360 days, outperforming placebo plus LLT by 35%. Data presented at ESC.Entresto(sacubitril/ valsartan)Data from the Phase IV PARACHUTE-HF study in patients with heart failure with reduced ejection fraction due to chronic Chagas disease showed that Entresto outperformed enalapril on a composite endpoint of cardiovascular death, heart failure hospitalization or NT-proBNP change. Entresto was well tolerated, with no new safety signals identified. Data presented at ESC.Kesimpta(ofatumumab)In the ARTIOS Phase IIIb study, patients with RMS who switched to Kesimpta after breakthrough disease on fingolimod or fumarate-based therapies showed a substantial reduction in disease activity. This was reflected in a low annualized relapse rate (ARR of 0.06 over 96 weeks), near-complete suppression of MRI activity, and over 90% of participants achieving no evidence of disease activity (NEDA-3). No new safety concerns were identified, regardless of prior disease-modifying treatment.In the separate ALITHIOS open-label extension study, more than 90% of naïve patients receiving Kesimpta showed no evidence of disease activity (NEDA-3) at 7 years, with no new safety concerns, reinforcing the benefit of introducing Kesimpta early. Data from both studies presented at ECTRIMS.Selected transactionsNovartis entered into an agreement to acquire Tourmaline Bio, a clinical-stage biopharmaceutical company developing pacibekitug, a Phase III-ready anti-IL-6 monoclonal antibody for atherosclerotic cardiovascular disease (ASCVD). In Phase II, pacibekitug reduced median high-sensitivity C-reactive protein (hsCRP) levels by up to 86% compared to placebo, with similar incidence rates of adverse events and serious adverse events. The transaction is expected to close on October 28, 2025.Novartis entered a second collaboration with Monte Rosa Therapeutics, in addition to the existing license agreement for VAV1 degraders, announced in October 2024. Under the new agreement, Novartis receives an exclusive license to an undisclosed discovery target and options to license two programs from Monte Rosa’s preclinical immunology portfolio.Novartis continued its collaboration with Argo Biopharma, adding two new agreements: an exclusive license to an siRNA candidate currently in IND-enabling studies and expected to enter Phase I in 2026, and an option to exclusively license two second-generation siRNA molecules currently in development, with a right of first negotiation to the Phase II ANGPTL3 program.Novartis entered into a global licensing and collaboration agreement with Arrowhead Pharmaceuticals for ARO-SNCA, a preclinical-stage siRNA therapy targeting alpha-synuclein for the treatment of synucleinopathies such as Parkinson’s disease. The agreement also includes additional collaboration targets leveraging Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform. Capital structure and net debt Retaining a good balance between investment in the business, a strong capital structure, and attractive shareholder returns remains a priority. During the first nine months of 2025, Novartis repurchased a total of 66.4 million shares for USD 7.5 billion on the SIX Swiss Exchange second trading line. These repurchases included 49.1 million shares (USD 5.4 billion) under the USD 15 billion share buyback (announced in July 2023 and completed in July 2025) and 6.6 million shares (USD 0.8 billion) under the new up-to USD 10 billion share buyback announced in July 2025. In addition, 10.7 million shares (USD 1.3 billion) were repurchased to mitigate anticipated full-year dilution related to the equity-based compensation plans of associates. Further, 1.6 million shares (equity value of USD 0.2 billion) were repurchased from associates. In the same period, 11.7 million shares (equity value of USD 0.9 billion) were delivered to associates related to equity-based compensation plans. Consequently, the total number of shares outstanding decreased by 56.3 million versus December 31, 2024. These treasury share transactions resulted in an equity decrease of USD 6.8 billion and a net cash outflow of USD 7.7 billion. Net debt increased to USD 20.4 billion at September 30, 2025, compared to USD 16.1 billion at December 31, 2024. The increase was mainly due to the free cash flow of USD 15.9 billion being more than offset by the USD 7.8 billion annual dividend payment, cash outflows for treasury share transactions of USD 7.7 billion and net cash outflow for M&A, intangible assets transactions and other acquisitions of USD 3.7 billion. As of Q3 2025, the long-term credit rating for the company is Aa3 with Moody’s Ratings and AA- with S&P Global Ratings. 2025 outlook Barring unforeseen events; growth vs. prior year in ccNet salesExpected to grow high single-digit Core operating incomeExpected to grow low-teens Foreign exchange impact If late-October exchange rates prevail for the remainder of 2025, the foreign exchange impact for the year would be neutral to positive 1 percentage point on net sales and negative 2 percentage points on core operating income. The estimated impact of exchange rates on our results is provided monthly on our website. Key figures1 Q3 2025Q3 2024% change9M 20259M 2024% change USD mUSD mUSDcc USD mUSD mUSDccNet sales13 90912 82387 41 19637 1641111Operating income4 5013 6272427 14 02811 0142731As a % of sales32.428.3 34.129.6 Net income3 9303 1852325 11 5639 1192729EPS (USD)2.041.582931 5.944.503235Net cash flows fromoperating activities6 5716 2865 16 88013 42626 Non-IFRS measures Free cash flow6 2175 9654 15 94112 61826 Core operating income5 4605 14567 16 96014 6351618As a % of sales39.340.1 41.239.4 Core net income4 3304 13356 13 52211 8221417Core EPS (USD)2.252.06910 6.945.831921 1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 42 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. Detailed financial results accompanying this press release are included in the Condensed Interim Financial Report at the link below:https://ml-eu.globenewswire.com/resource/download/7781ab26-6902-4024-a9c8-49124629eb37/ DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “anticipate,” “can,” “will,” “continue,” “ongoing,” “growth,” “launch,” “expect,” “expand,” “deliver,” “accelerate,” “guidance,” “outlook,” “priority,” “potential,” “momentum,” “commitment,” or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding results of ongoing clinical trials; or regarding potential future, pending or announced transactions; regarding potential future sales or earnings; or by discussions of strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or regarding our capital structure. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. Neither can there be any guarantee that the expected benefits or synergies from the transactions described in this press release will be achieved in the expected timeframe, or at all. In particular, our expectations could be affected by, among other things: uncertainties concerning global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding the success of key products, commercial priorities and strategy; uncertainties in the research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; uncertainties regarding our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; uncertainties in the development or adoption of potentially transformational digital technologies, including artificial intelligence, and business models; uncertainties surrounding the implementation of our new IT projects and systems; uncertainties regarding potential significant breaches of information security or disruptions of our information technology systems; uncertainties regarding actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; our performance on and ability to comply with environmental, social and governance measures and requirements; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. All product names appearing in italics are trademarks owned by or licensed to Novartis. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X and Instagram. Novartis will conduct a conference call with investors to discuss this news release today at 14:00 Central European time and 9:00 Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Novartis website. A replay will be available after the live webcast by visiting https://www.novartis.com/investors/event-calendar. Detailed financial results accompanying this press release are included in the Condensed Interim Financial Report at the link below. Additional information is provided on our business and pipeline of selected compounds in late-stage development. A copy of today's earnings call presentation can be found at https://www.novartis.com/investors/event-calendar. Important dates October 30, 2025 Immunology pipeline event at ACR (virtual)November 19-20, 2025Meet Novartis Management 2025 (London, UK)December 1, 2025Social Impact & Sustainability annual investor event (virtual)February 4, 2026Fourth quarter & full year 2025 results # # # Novartis Media RelationsE-mail: media.relations@novartis.comNovartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com Please find full media release in English attached and on the following link:Media Release (PDF) Further language versions are available through the following links: German version is available through the following link:Medienmitteilung (PDF)

Clinical ResultPhase 3License out/inPhase 2Phase 1

100 Deals associated with Ribociclib Succinate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Ribociclib Succinate	L01XE	DB11730

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Advanced breast cancer	Canada	Novartis Pharmaceuticals Canada, Inc.	02 Mar 2018
Metastatic breast cancer	Canada	Novartis Pharmaceuticals Canada, Inc.	02 Mar 2018
Hormone receptor positive HER2 negative breast cancer	United States	Novartis Pharmaceuticals Corp.	13 Mar 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced HER2-Positive Breast Carcinoma	Phase 3	United States	Novartis AG	28 Mar 2022
Advanced HER2-Positive Breast Carcinoma	Phase 3	Portugal	Novartis AG	28 Mar 2022
Advanced HER2-Positive Breast Carcinoma	Phase 3	Spain	Novartis AG	28 Mar 2022
Early Stage Breast Carcinoma	Phase 3	-	Novartis Pharmaceuticals Corp.	31 Mar 2018
HER2-negative breast cancer	Phase 3	Italy	Novartis Pharmaceuticals Corp.	02 Feb 2018
Leukodystrophy, Hypomyelinating, 6	Phase 3	Italy	Novartis Pharmaceuticals Corp.	02 Feb 2018
Locally advanced breast cancer	Phase 3	Italy	Novartis Pharmaceuticals Corp.	02 Feb 2018
Breast Cancer	Phase 3	United States	Novartis Pharmaceuticals Corp.	07 Jun 2017
Advanced cancer	Phase 3	United States	Novartis Pharmaceuticals Corp.	30 Nov 2016
Advanced cancer	Phase 3	Argentina	Novartis Pharmaceuticals Corp.	30 Nov 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2025	Not Applicable	Hormone receptor positive HER2 negative breast cancer First line HR+/HER2-	11,557	Palbociclib+AI	kycxywdfco(lrcvidpvof) = jayblttzfa hiecaxjoca (jdbodhburu ) View more	Positive	17 Oct 2025
				Ribociclib+AI	kycxywdfco(lrcvidpvof) = ivqdgoybvv hiecaxjoca (jdbodhburu ) View more
REALEESA (ESMO2025)	Not Applicable	Hormone receptor positive HER2 negative breast cancer HR+/HER2-	132	Ribociclib plus HT	ebelnfcijy(bunwmstbjj) = Musculoskeletal disorders were the most frequent AE (46.3%), followed by infections (24.4%) and neutropenia (20.7%). czlsidtybc (iuakijaqec )	Positive	17 Oct 2025
NATALEE (ESMO2025)	Phase 3	Early Stage Breast Carcinoma Adjuvant HR+/HER2−	3,738	Ribociclib + NSAI	blgrfuscrg(iiafuinkqh) = bbdjqltvri ajkacwfboj (mbzdvjbzwt ) View more	Positive	17 Oct 2025
				NSAI alone	blgrfuscrg(iiafuinkqh) = ppbyqpxswi ajkacwfboj (mbzdvjbzwt ) View more
ESMO2025	Not Applicable	Hormone receptor positive HER2 negative breast cancer HR+ \| HER2-	6,796	Palbociclib + Palbociclibherapy	qomunvelyt(cftlygdeoy): HR = 0.81 (95.0% CI, 0.66 - 0.99), P-Value = 0.043 View more	Positive	17 Oct 2025
				Ribociclib + RibociclibTherapy
NCT03701334 (NATALEE, ESMO2025)	Phase 3	Neoadjuvant HR+/HER2−	2,180	ribociclib+NSAI	ltecuwfavy(flvjxyjshr) = eimnejzxog knmnmjixpg (zmmvxbjfcb ) View more	Positive	17 Oct 2025
				NSAI alone	ltecuwfavy(flvjxyjshr) = rbbgjqbvyb knmnmjixpg (zmmvxbjfcb ) View more
NCT05508906 (ESMO2025)	Phase 1/2	ER-positive/HER2-negative Breast Cancer ER+ \| HER2-	72	Palazestrant 120 mg plus ribociclib	hyclzxnocu(jxhxaoboht) = 35% dlwkwxaqix (ssxudpkbiy ) View more	Positive	17 Oct 2025
				Palazestrant 120 mg plus ribociclib (prior CDK4/6i)
NCT05296746 (RIBOLARIS, ESMO2025)	Phase 2	ER-positive/HER2-negative Breast Cancer Neoadjuvant HR+ \| HER2-	686	Ribociclib + Endocrine Therapy	eyhzoulvdf(hycpnipjyf) = mfyqdaitpo lwallqoftl (snjumxeoxb, 10.5 - 12.2)	Positive	17 Oct 2025
ESMO2025	Not Applicable	Advanced breast cancer HR+ \| HER2-	16	Camizestrant	-	Positive	17 Oct 2025
				Ribociclib plus ET
ESMO2025	Not Applicable	Hormone receptor positive HER2 negative breast cancer HR+/HER2−	352	Ribociclib plus endocrine therapy	etwrovonhl(edyqkcieza) = lgdapnmbrx vbhagcgcqs (cuhqzjmiqt, 0.94 - 1.27) View more	Negative	17 Oct 2025
ESMO2025	Not Applicable	Hormone receptor positive HER2 negative breast cancer	270	Ribociclib as first-line (1L)	dkdwiakqii(btghuozexh) = Most common AEs were neutropenia (151, 55.9%), fatigue/asthenia (36, 13.3%), anemia (33, 12.2%), and leukopenia (25, 9.3%). nkhthktbio (xvogqffgfm ) View more	Positive	17 Oct 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis